NCT04015934

Brief Summary

The cornerstone treatment for multifocal motor neuropathy (MMN), a rare and disabling dysimmune neuropathy, is intravenous immunoglobulin (IVIg). The aim of this study is to identify prognostic factors of poor outcome. Data were retrospectively collected from MNN patients in three French centers. Patients were divided into two groups: a good outcome group and a poor outcome group. Demographic, clinical, biological and nerve conduction study features of MMN patients were analyzed. Identification of prognostic factors in MMN could help develop personalized treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 31, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 11, 2019

Completed
Last Updated

July 11, 2019

Status Verified

May 1, 2019

Enrollment Period

7 months

First QC Date

May 31, 2019

Last Update Submit

July 10, 2019

Conditions

MMN

Keywords

predictive factors

Outcome Measures

Primary Outcomes (1)

  • Presence of deteriorating or strongly dependant IVIg NMM

    inclusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MMN patients

You may qualify if:

  • diagnosis of MNN following the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline criteria 2010

You may not qualify if:

  • missing data
  • clinical progression features suggested another inflammatory neuropathy,
  • immunosuppressive agents for another pathology.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central Hospital

Nancy, 54000, France

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2019

First Posted

July 11, 2019

Study Start

April 1, 2018

Primary Completion

November 1, 2018

Study Completion

February 1, 2019

Last Updated

July 11, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)